The Massachusetts Institute of Technology will be aiming to design and install a new continuous mRNA manufacturing platform, with help from the federal government.
According to MIT on Thursday, the project, backed by $82 million from the FDA’s Center for Biologics Evaluation and Research over three years, will aim to advance the field of mRNA therapeutics by providing a continuous manufacturing template for other companies to follow, while facilitating collaboration throughout the biopharma industry.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters